Suppr超能文献

[糖皮质激素性骨质疏松症:最新研究成果]

[Glucocorticoid-induced osteoporosis: recent findings].

作者信息

Angeli A, Osella G, Reimondo G, Terzolo M

机构信息

Dipartimento di Scienze Cliniche e Biologiche, Università degli Studi di Torino.

出版信息

Ann Ital Med Int. 2000 Jan-Mar;15(1):47-55.

Abstract

The clinical features, pathogenesis and management of bone involvement in Cushing's syndrome are briefly reviewed. Personal data on bone mineral density and markers of bone turnover in Cushing's syndrome and adrenal incidentalomas are also reported. As long ago as 1932, Harvey Cushing recognized osteoporosis as a serious consequence of endogenous hypercortisolism. The introduction of cortisone in the therapy of autoimmune, rheumatic, allergic or dermatologic disorders was followed by several reports of detrimental effects on bone of patients who had undergone prolonged glucocorticoid treatment. Due to the rarity of Cushing's syndrome, most of the studies in the literature on glucocorticoid-induced osteoporosis refer to exogenous over-exposure to cortisone and its synthetic derivatives. Only a small number of works concern endogenous hypercortisolism, even if the characteristics of bone damage seem qualitatively the same. Finally, very few data are reported on the hypothetical detrimental effect on bone in the condition of the silent hypercortisolism of adrenal incidentalomas. Glucocorticoid-induced osteoporosis in Cushing's syndrome often results in vertebral fractures, and bone loss is more evident in trabecular than in cortical bone. Notwithstanding some distinctive features in osteoporosis induced by endogenous and exogenous glucocorticoid excess, the common eventual picture is notable bone damage that involves mainly the trabecular bone. Prompt and effective therapy is mandatory to reduce the risk of fractures. The present options include calcium and vitamin D supplementation, estrogen replacement therapy, bisphosphonates, either oral or parenteral. A novel approach to the clinical problem of glucocorticoid-induced osteoporosis might, in the future, be based on studies on selective glucocorticoid receptor modulators, a new class of synthetic glucocorticoids that exhibit significant anti-inflammatory and immunosuppressive activities, with reduced side effects on bone.

摘要

本文简要回顾了库欣综合征骨受累的临床特征、发病机制及治疗方法。同时报告了库欣综合征和肾上腺偶发瘤患者骨密度及骨转换标志物的个人数据。早在1932年,哈维·库欣就认识到骨质疏松是内源性皮质醇增多症的严重后果。在将可的松用于自身免疫性、风湿性、过敏性或皮肤病的治疗后,有几份报告指出长期接受糖皮质激素治疗的患者骨骼受到了有害影响。由于库欣综合征较为罕见,文献中大多数关于糖皮质激素诱导骨质疏松症的研究都涉及外源性过量接触可的松及其合成衍生物。只有少数研究关注内源性皮质醇增多症,即便骨损伤的特征在本质上似乎相同。最后,关于肾上腺偶发瘤隐匿性皮质醇增多症对骨骼的潜在有害影响,报告的数据非常少。库欣综合征中糖皮质激素诱导的骨质疏松症常导致椎体骨折,小梁骨的骨质流失比皮质骨更明显。尽管内源性和外源性糖皮质激素过量导致的骨质疏松症有一些独特特征,但常见的最终情况是主要累及小梁骨的明显骨损伤。必须采取迅速有效的治疗措施以降低骨折风险。目前的选择包括补充钙和维生素D、雌激素替代疗法、口服或胃肠外双膦酸盐。未来,针对糖皮质激素诱导骨质疏松症这一临床问题的新方法可能基于对选择性糖皮质激素受体调节剂的研究,这是一类新型合成糖皮质激素,具有显著的抗炎和免疫抑制活性,对骨骼的副作用较小。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验